PRINCETON, N.J.—Pharmaceutical research service specialist Covance announced recently it has licensed the B-CLEAR pharmacokinetics platform from North Carolina-based Qualyst. It is expected that the platform will help Covance customers by limiting the late-stage drug candidate failures that, according to a Frost & Sullivan report, cost companies $50-70 million per failure.
"We're looking to B-CLEAR to help our customers identify and select better drug candidates," said Jon Denissen, Covance VP of chemistry in North America. "Adding B-CLEAR greatly compliments our existing strengths in metabolism and pharmacokinetic services that help drug researchers to improve candidate selection and progress drug candidates that have a higher chance for success."
Enhancing Covance's pharmaceutical research service, the platform will be used for in vitro assessment and in vivo prediction of drug properties such as hepatobiliary disposition, hepatic uptake and accumulation, biliary clearance and drug transport. Financial terms were not disclosed.